Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Scientific Reports|November 23, 2019
Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancerStella D'Oronzo, Domenica Lovero, Raffaele Palmirotta, et al.
Acta Dermato-Venereologica|April 13, 2018
Effect of Age on Melanoma Risk, Prognosis and Treatment ResponseSimone Ribero, Luigia Stefania Stucci, Elena Marra, et al.
Expert Reviews in Molecular Medicine|September 13, 2018
Animal-type melanoma: dog or wolf? A review of the literature and a case reportLuigia Stefania Stucci, Raffaele Palmirotta, Domenica Lovero, et al.
International Journal of Molecular Sciences|August 6, 2020
Non-Melanoma Skin Cancers: Biological and Clinical FeaturesMauro Cives, Francesco Mannavola, Lucia Lospalluti, et al.
Scientific Reports|May 9, 2025
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regionsRaffaele Ardito, Grazia Arpino, Roberta Caputo, et al.
Nutrition & Metabolism|May 30, 2019
Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspectiveMaria Neve Ombra, Panagiotis Paliogiannis, Luigia Stefania Stucci, et al.
Oncotarget|March 20, 2018
Current status and perspectives in immunotherapy for metastatic melanomaRiccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, et al.
Therapeutic Advances in Drug Safety|April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patientsStefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
Cancer Treatment Reviews|June 5, 2018
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitorsLuigia Stefania Stucci, Stella D'Oronzo, Marco Tucci, et al.
Breast (Edinburgh, Scotland)|October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclibMarzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
Pageof 6